Get the Stockscreener App
72.60
0.76%
0.55
After Hours:
72.85
0.25
+0.34%
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $72.60, with a volume of 2.46M.
It is up +0.76% in the last 24 hours and down -7.27% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$72.05
Open:
$72.515
24h Volume:
2.46M
Relative Volume:
1.21
Market Cap:
$35.62B
Revenue:
$10.03B
Net Income/Loss:
$1.07B
P/E Ratio:
33.69
EPS:
2.1549
Net Cash Flow:
$1.39B
1W Performance:
-5.49%
1M Performance:
-7.27%
6M Performance:
-18.98%
1Y Performance:
-24.91%
1-Day Range:
$72.47
$73.12
1-Week Range:
$71.55
$77.00
52-Week Range:
$71.55
$99.20
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
72.60 | 35.62B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
ISRG
Intuitive Surgical Inc
|
435.73 | 154.00B | 9.15B | 2.63B | 1.99B | 7.1661 |
|
BDX
Becton Dickinson Co
|
186.66 | 53.47B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
RMD
Resmed Inc
|
273.01 | 39.70B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
WST
West Pharmaceutical Services Inc
|
262.47 | 18.82B | 2.96B | 487.70M | 344.00M | 6.6758 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-20-25 | Downgrade | Deutsche Bank | Buy → Hold |
| May-14-25 | Reiterated | BTIG Research | Buy |
| Mar-28-25 | Reiterated | Needham | Buy |
| Mar-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-24-25 | Reiterated | Needham | Buy |
| Jan-10-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Dec-17-24 | Reiterated | Needham | Buy |
| Nov-12-24 | Reiterated | Needham | Buy |
| Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-10-24 | Initiated | Goldman | Buy |
| Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-23-24 | Initiated | Bernstein | Outperform |
| Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
| Dec-22-22 | Initiated | Mizuho | Buy |
| Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
| Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-11-22 | Initiated | BofA Securities | Buy |
| Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Initiated | Oppenheimer | Perform |
| Jul-14-21 | Initiated | Deutsche Bank | Buy |
| May-06-21 | Upgrade | Citigroup | Sell → Neutral |
| Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
| Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Argus | Hold → Buy |
| Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
| Mar-13-20 | Upgrade | UBS | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
| Jan-08-20 | Initiated | Argus | Hold |
| Oct-29-19 | Initiated | Stephens | Equal-Weight |
| Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
| Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
| Jun-14-19 | Initiated | BTIG Research | Neutral |
| May-10-19 | Initiated | Robert W. Baird | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
How Alcon Inc. stock performs in stagflationWatch List & Free Verified High Yield Trade Plans - newser.com
Vision Care: Global Market Report 2025 | Leading Vision - GlobeNewswire
Barclays Initiates Coverage on Alcon (ALC) with Equal-Weight Rat - GuruFocus
Alcon Inc. stock trend outlook and recovery pathTrade Volume Summary & Safe Entry Zone Tips - newser.com
Barclays reiterates Equalweight rating on Alcon stock, maintains $86 price target - Investing.com Australia
Is Alcon Inc. (2U3) stock inflation resilientWeekly Trade Review & Real-Time Stock Movement Alerts - newser.com
Broadwood slams STAAR board over “carelessness” in Alcon sale defense - Investing.com
Is Alcon Now an Opportunity After 29.6% Share Price Slide in 2024? - Yahoo Finance
Alcon stock hits 52-week low at 73.17 USD By Investing.com - Investing.com Canada
Broadwood urges STAAR shareholders to reject Alcon acquisition By Investing.com - Investing.com Canada
Broadwood urges STAAR shareholders to reject Alcon acquisition - Investing.com
Alcon stock hits 52-week low at 73.17 USD - Investing.com
Investor Group Opposes Alcon's Acquisition of STAAR Surgical (AL - GuruFocus
Broadwood issues letter to Staar Surgical board questioning ‘rush’ in Alcon sale - TipRanks
Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale - MarketScreener
How to integrate Alcon Inc. into portfolio analysis toolsStop Loss & Accurate Trade Setup Notifications - newser.com
Short interest data insights for Alcon Inc.Day Trade & Precise Buy Zone Tips - newser.com
Can trapped investors hope for a rebound in Alcon Inc.Bond Market & Community Verified Watchlist Alerts - newser.com
Alcon Stock Rated Buy by BTIG Following TRYPTYR Approval - MSN
What hedge fund moves indicate for Alcon Inc. Ordinary Shares stockNew Guidance & Intraday High Probability Alerts - newser.com
How to forecast Alcon Inc. trends using time seriesTrade Ideas & Daily Price Action Insights - newser.com
What to do if you’re stuck in Alcon Inc.2025 Sector Review & Daily Oversold Bounce Ideas - newser.com
STAAR Surgical Board Defends $1.5 Billion Alcon Acquisition Plan - Finimize
Glass Lewis recommends shareholders vote against STAAR-Alcon deal By Investing.com - Investing.com Nigeria
STAAR urges shareholders to approve Alcon merger despite Glass Lewis report - Investing.com Nigeria
STAAR Surgical’s Long-Term Shareholder Says Proposed Deal With Alcon Undervalues The Company - MSN
Alcon (ALC) Faces Opposition in Staar Surgical Merger Deal - GuruFocus
STAAR Surgical (STAA): Proxy Adviser Urges Rejection of Alcon De - GuruFocus
STAAR urges shareholders to approve Alcon merger despite Glass Lewis report By Investing.com - Investing.com South Africa
Glass Lewis Advises Against Alcon (ALC) Acquisition of STAAR - GuruFocus
STAAR Surgical holders should vote against sale to Alcon, Glass Lewis says - Seeking Alpha
Broadwood and Glass Lewis urge Staar shareholders to vote "against" sale to Alcon - MarketScreener
Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon - The Globe and Mail
Broadwood urges STAAR shareholders to reject Alcon takeover bid - Investing.com
Broadwood Partners Questions Integrity of STAAR Surgical’s Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon | FinancialContent - FinancialContent
Defender Capital Opposes STAAR Surgical's Proposed Acquisition By Alcon - Nasdaq
Defender Capital Opposes STAAR Surgical?s Sale to Alcon - MarketScreener
Alcon's Proposed Acquisition of STAAR Faces Shareholder Oppositi - GuruFocus
Warner Bros. Challenges Alcon Bid for ‘Matrix’ Studio Rights - Bloomberg Law News
Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon - Stock Titan
Yunqi Capital, One Of Staar Surgical Company’S Largest Shareholders, Reiterates Its Opposition To The Proposed Merger With Alcon - TradingView
Yunqi Capital opposes sale of STAAR Surgical to Alcon - Investing.com
Yunqi Capital opposes sale of STAAR Surgical to Alcon By Investing.com - Investing.com Nigeria
Yunqi Capital Challenges Proposed Sale of STAAR to Alcon (ALC) - GuruFocus
Yunqi Capital urges STAAR shareholders to oppose Alcon merger - TipRanks
$62/Share Offer Challenged: STAAR Shareholder Yunqi (5.1%) Reiterates Opposition Ahead of Vote - Stock Titan
Dry Eye Disease Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | AbbVie, Allergan, AFT Pharmaceuticals, Akorn, Alcon Inc., Bausch Health - Barchart.com
STAAR Surgical Faces Shareholder Clash Over Alcon Buyout - Finimize
How Alcon Inc. Ordinary Shares stock benefits from digital adoptionWeekly Profit Summary & Weekly Momentum Picks - newser.com
Broadwood urges STAAR shareholders to reject $28 per share Alcon deal - Investing.com
Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Judgment in Proposed Sale to Alcon - Stock Titan
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
3.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):